Endothelin-1 and endothelin converting enzyme-1 in human atherosclerosis - Novel targets for pharmacotherapy in atherosclerosis

Current Vascular Pharmacology

Volumn 2, Issue 3, 2004, Pages 249-258

  Ihling, C ^a   Bohrmann, B ^a   Schaefer, H E ^a   Technau Ihling, K ^a   Loeffler, B M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Angina; Atherosclerosis; Chronic inflammation; Endothelin converting enzyme; Endothelin 1; Plaque rupture

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME;

ADULT; ATHERECTOMY; BLOOD VESSEL TONE; CELL GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; ENDOTHELIUM CELL; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PROTEIN DETERMINATION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; REVIEW; UPREGULATION; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ASPARTIC ENDOPEPTIDASES; ATHEROSCLEROSIS; CORONARY VESSELS; ENDOTHELIN-1; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMARY ARTERIES; METALLOENDOPEPTIDASES; MICROSCOPY, IMMUNOELECTRON; RECEPTOR, ENDOTHELIN A; TUNICA INTIMA;

EID: 3042745180     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570161043385718     Document Type: Review

References (58)

1. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989; 86: 2863-2867.
2. Kochva E, Bdolah A, Wollberg Z. Sarafotoxins and endothelins: evolution, structure and function. Toxicon 1993; 31: 541-568.
3. Ishida N, Tsujioka K, Tomoi N, Saida K, Mitsui Y. Differential activities of two distinct endothelin family peptides on ileum and coronary artery. FEBS Lett 1989; 247: 337-340.
4. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332: 411-415.
5. Battistini B, D'Orleans-Juste P, Sirois P. Endothelins: Circulating plasma levels and presence in other biologic fluids. Lab Invest 1993; 68: 600-617.
6. Murch SH, Braegger CP, Sessa WC, Mac Donald TT. High endothelin-1 immunoreactivity in Crohn's disease and ulcerative colitis. Lancet 1992; 339: 381-395.
7. Appleton I, Tomlinson A, Chander CL, Willoughby DA. Effect of endothelin-1 on croton oil-induced granulation tissue in the rat. Lab Invest 1992, 67: 703-710.
8. Kagugawa Y, Giaid A, Yanagisawa M, Greenstein-Baynash A, Melnyk P, Rosenberg L, et al. Expression of endothelin-1 in pancreatic tissue of patients with chronic pancreatitis. J Pathol 1996; 178: 78-83.
9. Schiffrin EL. Endothelin. Potential role in hypertension and vascular hypertrophy. Hypertension 1995; 25: 1135-1142.
10. Lerman A, Edwards BS, Halett JW, Heublein D, Sandberg S, Burnett JC, Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325: 997-1001.
11. Lerman A, Webster MWI, Chesebro JH, Edwards WD, Wei C-M, Fuster V, et al. Circulating and tissue endothelin immunoreactivity in hypercholesterolemic pigs. Circulation 1993; 88: 2923-2928.
12. Opgaard O, Cantera L, Adner M, Edvinsson L. Endothelin-A and - B receptors in human coronary arteries and veins. Regul Pept 1996; 63: 149-156.
13. Knott PG, A'Aprile AC, Henry PJ, et al. Receptors for endothelin-1 in asthmatic human peripheral lung. Br J Pharmacol 1995; 114: 1-3.
14. Yanagisawa, Boulanger C, Lüscher TF. Hirudin and nitrates inhibit the thrombin-induced release of endothelin from the intact porcine aorta. Circ Res 1991; 68: 1768-1772.
15. Denault JB, Claing A, D'Orleans-Juste P, Sawamura T, Kido T, Masaki T, et al. Processing of proendothelin-1 by human furin convertase. FEBS Lett 1995; 362: 276-280.
16. Opgenorth TJ, WU-Wong JR, Shiosaki K. Endothelin-converting enzymes. FASEB J 1992; 6: 2653-2659.
17. Shimada K, Takahashi M, Tanzawa K. Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. J Biol Chem 1994; 269: 18275-18278.
18. Xu D, Emoto N, Giad A, Slaughter C, Kaw S, DeWit D, et al. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 1994; 78: 473-485.
19. Emoto N, Yanagisawa M. Endothelin-converting enzyme-2 is a membrane bound, phosphoramidon-sensitive metalloproteinase with acidic pH optimum. J Biol Chem 1995; 270: 15262-15268.
20. Schweizer A, Valdenaire O, Nelböck P, Deuschle U, Dumas M, Stumpf J, et al. Human endothelin-converting enzyme (ECE-1): three isoforms with distinct subcellular localizations. Biochem J 1997; 328: 871-877.
21. Komuro I, Kurihara I, Sugiyama T, Takaku F, Yazaki Y. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett 1988; 238: 249-252.
22. Hirata Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 1989; 78: 225-228.
23. Brown KD, Littlewood CJ. Endothelin stimulates DNA synthesis in Swiss 3T3 cells. Synergy with polypeptide growth factors. Biochem J 1989; 263: 977-980.
24. Yoshizumi M, Kim S, Kagami S, Hamaguchi A, Tsuchiya K, Kouchi H, et al. Effect of endothelin-1 (1-31) on extracellular signal-regulated kinase and proliferation of human coronary artery smooth muscle cells. Br J Pharmacol 1998; 125: 1019-1027.
25. A receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 1998; 24: 14367-14372.
26. Ross R. Atherosclerosis - An inflammatory disease. N Engl J Med 1998; 340: 115-126.
27. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993; 69: 377-381.
28. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation 1994; 90: 775-778.
29. van der Wall AC, Becker AE, van der Loos CM, Das PK. The site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994; 89: 36-44.
30. Bogarty P, Hackett D, Davies G, Maseri A. Vasoreactivity of the culprit lesion in untable angina. Circulation 1994; 90: 5-11.
31. Ehrenreich H, Andreson RW, Fox CH, Rieckmann P, Hoffman GS, Travis WD, et al. Endothelins, peptides with potent vasoactive poperties, are produced by human macrophages. J Exp Med 1990; 172: 1741-1748.
32. Sessa WC, Kaw S, Hecker M, Vane JR. The biosynthesis of endothelin-1 by human polymorphonuclear leukocytes. Biochem Biophys Res Common 1991; 174: 613-618.
33. Yang Z, Richard D, Von Segesser L, Bauer E, Stulz P, Turina M, et al. Treshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries: a new mechanism of vasospasm? Circulation 1990; 82: 188-195.
34. Minamino T, Kurihara H, Takahashi M, Shimada K, Maemura K, Oda H, et al. Endothelin-converting enzyme expression in the rat vascular injury model and human coronary atherosclerosis. Circulation 1997; 95: 221-230.
35. Maguire J, Davenport A. Increased response to big endothelin-1 in atherosclerotic human coronary artery: functional evidence for upregulation of endothelin-converting enzyme activity in disease. Br J Pharmacol 1998; 125: 238-240.
36. Ihling C, Szombathy T, Bohrmann B, Brockhaus M, Schaefer HE, Loeffler BM. Coexpression of endothelin-converting enzyme-1 and endothelin-1 in different stages of human atherosclerosis. Circulation 2001; 104: 864-869.
37. Ihling C, Göbel H, Lippoldt A, Wessels S, Paul M, Schaefer HE, et al. Endothelin-1-like-immunoreactivity in human atherosclerotic coronary tissue: A detailed analysis of the cellular distribution of endothelin-1. J Pathol 1996; 179: 303-308.
38. Zeiher AM, Goebel H, Schächinger V, Ihling C. Tissue endothelin-1 immunoreactivity in the active coronay atherosclerotic plaque: a clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation 1995; 91: 941-947.
39. Zeiher AM, Ihling C, Pistorius K, Schächinger V, Schaefer HE. Increased tissue endothelin immunoreactivity in atherosclerotic lesions associated with acute coronary syndromes. Lancet 1994; 344: 1405-1406.
40. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. Arterioscl Thromb Vasc Biol 1995; 15: 1512-1531.
41. Hinohara T, Selmon MR, Robertson GC, Braden L, Simpson JB. Directional atherectomy: new approaches for treatment of obstructive coronary and peripheral vascular disease. Circulation 1990, 81 (suppl IV): IV-79-91.
42. Ando K, Hirata Y, Shichiri M, Emori T, Maruomo F. Presence of immunoreactive endothelin in human plasma. FEBS Lett 1989, 245: 164-166.
43. Heublein D, Rodeheffer RJ, Cavero PG, Miller WL, Edwards BS, Redfield MM, et al. Relationship between plasma endothelin and atrial natriuretic factor in humans with congestive heart failure. Am J Hypertens 1999; 2: 37A.
44. Lerman A, Hildebrand FL Jr, Margulies KB, O'Murchu B, Perella MA, Heublein DM, et al. Endothelin: a new cardiovascular regulatory peptide. Mayo Clin Proc 1990; 65: 1441-1455.
45. Hiroe M, Hirata Y, Marumo F, Nagata M, Toyozaki T, Hasumi M, et al. Immunohistochemical localization of endothelin in human vascular endothelial cells. Peptides 1989; 10: 1281-1282.
46. Miyauchi T, Tomobe Y, Shiba R, Ishikawa T, Yanagisawa M, Kimura S, et al. Involvement of endothelin in the regulation of human vascular tonus: potent vasoconstrictor effect and existence in endothelial cells. Circulation 1990; 81: 1874-1880.
47. Sessa WC, Kaw S, Zembowicz A, Anggard E, Hecker M, Vane JR. Human polymorphonuclear leukocytes generate and degrade endothelin-1 by two distinct neutral proteases. J Cardiovasc Pharmacol 1991; 17 Suppl 7: 34-38.
48. Hoff HF, Gaubatz JW. Isolation, purification and characterization of lipoproteins containing apo B from the human aorta. Atherosclerosis 1982; 42: 273-297.
49. Clevidence BA, Morton RE, West G, Dusek DM, Hoff HF. Cholesterol esterification in macrophages. Stimulation by lipoproteins containing apo B isolated from human aortas. Arteriosclerosis 1984; 4: 196-207.
50. Raymond TL, Reynolds SA: Lipoproteins of the extracellular space: alterations in low density lipoproteins of interstitial inflammatory fluid. J Lipid Res 1983; 24: 113-119.
51. Raymond TL, Reynolds SA. Direct modification of plasma low-density lipoproteins in interstitial inflammatory fluid of the rabbit. Inflammation 1984; 8: 337-342.
52. Martin-Nizard F, Houssaini HS, Lestavel-Delattre S, Duriez P, Fruchard J-C. Modified low density lipoproteins activate human macrophages to secrete immunoreactive endothelin. FEBS Lett 1991; 293: 127-130.
53. Bacon CR, Cary N, Davenport AP. Endothelin peptide and receptors in human atherosclerotic coronary artery and aorta. Circ Res 1996; 79: 794-801.
54. Fuster V, Stein B, Ambrose JA, Badimon L, Badimon JJ, Chesebro JH. Atherosclerotic Plaque rupture and thrombosis: Evoloving concepts. Circulation 1990; 82(suppl. I): II 47-59.
55. Grantham JA, Schirger JA, Williamson EE, Heublein DM, Wennberg PW, Kirchengast M, et al. Enhanced endothelin-converting enzyme immunoreactivity in early atherosclerosis. J Cardiovasc Pharmacol 1998; 31: Suppl: S22-26.
56. Hahn AWA, Resink TJ, Kern F, Bühler FR. Effects of endothelin-1 on vascular smooth muscle cell phenotypic differentiation. J Cardiovasc Pharmacol 1992; 20 Suppl 12: 533-536.
57. Gabbiani G, Hirschel BJ, Ryan GB, Statkov PR, Majno G. Granulation tissue as a contractile organ. A study of structure and function. J Exp Med 1972; 135: 719-734.
58. Barnes K, Brown C, Turner AJ. Endothelin-converting enzyme. Ultrastructural localization and its recycling from the cell surface. Hypertension 1998; 31: 3-9.